



A Pfizer Company

SAFETY DATA SHEET

Revision date: 14-Oct-2016

Version: 1.0

Page 1 of 8

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Fluconazole Injection (Hospira, Inc.)

Trade Name: Not established

Chemical Family: Synthetic class of compounds known as bis-triazoles

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antifungal agent

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Not Classified

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Additional Information:

For a more detailed discussion of potential health hazards and toxicity see Section 11.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

PZ03186

SAFETY DATA SHEET

Material Name: Fluconazole Injection (Hospira, Inc.)
Revision date: 14-Oct-2016

Page 2 of 8
Version: 1.0

3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Fluconazole	86386-73-4	Not Listed	Acute Tox. 4(H302) Repr. 1B (H360D) Lact. (H362) Aquatic Acute 3 (H402) Aquatic Chronic 3 (H412)	0.2
Sodium chloride	7647-14-5	231-598-3	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Dextrose, monohydrate	5996-10-1	Not Listed	Not Listed	*
Water for Injection	7732-18-5	231-791-2	Not Listed	*

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Carbon monoxide, carbon dioxide, nitrogen oxides and fluorine-containing compounds

SAFETY DATA SHEET

Material Name: Fluconazole Injection (Hospira, Inc.)
Revision date: 14-Oct-2016

Page 3 of 8
Version: 1.0

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Evacuate area and fight fire from a safe distance.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Clean spill area thoroughly. Use non-combustible absorbent material to wipe up spill and place in a sealed container for disposal.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Fluconazole

Pfizer OEL TWA-8 Hr: 500µg/m³

Sodium chloride

Latvia OEL - TWA 5 mg/m³

Lithuania OEL - TWA 5 mg/m³

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

SAFETY DATA SHEET

Material Name: Fluconazole Injection (Hospira, Inc.)
Revision date: 14-Oct-2016

Page 4 of 8
Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Hands:	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)
Eyes:	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)
Respiratory protection:	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Liquid	Color:	Colorless
Odor:	Odorless	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	4 - 8; 3.5 - 6.5 (sodium chloride solution) (dextrose solution)

Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Sodium chloride

No data available

Fluconazole

Predicted Log P 5.0

Dextrose, monohydrate

No data available

Water for Injection

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available

SAFETY DATA SHEET

Material Name: Fluconazole Injection (Hospira, Inc.)
Revision date: 14-Oct-2016

Page 5 of 8
Version: 1.0

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Protect from freezing
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.
Short Term: May cause irritation (based on components)
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver and the developing fetus.
Known Clinical Effects: Clinical use of this drug has caused headache, skin rash, vomiting, abdominal pain, and diarrhea. Fluconazole is found in human breast milk at concentrations similar to plasma. Therefore, nursing mothers should limit exposure. There have been reports of multiple congenital abnormalities in infants whose mothers were being treated for 3 or more months with high dose (400-800mg/day) fluconazole. Rare cases of serious liver damage and allergic reactions have been reported.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium chloride

Rat Oral LD50 3000 mg/kg
Mouse Oral LD50 4000 mg/kg

Fluconazole

Rat (F) Oral LD50 1575 mg/kg
Rat (M) Oral LD50 1325mg/kg
Mouse Oral LD50 1410mg/kg
Mouse (M) Oral LD50 1520mg/kg
Dog Intravenous LD50 > 100mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium chloride

Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Fluconazole

3 Month(s) Rat Oral 5 mg/kg/day NOAEL Liver
6 Month(s) Dog Oral 7.5 mg/kg/day NOAEL Liver
12 Month(s) Rat Oral 10 mg/kg/day LOAEL Liver
12 Month(s) Dog Oral 2.5 mg/kg/day NOAEL Liver

SAFETY DATA SHEET

Material Name: Fluconazole Injection (Hospira, Inc.)
Revision date: 14-Oct-2016

Page 6 of 8
Version: 1.0

11. TOXICOLOGICAL INFORMATION

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Fluconazole

Reproductive & Fertility	Rat	Oral 20 mg/kg/day	NOAEL	Negative
Embryo / Fetal Development	Rabbit	Oral 20 mg/kg/day	NOAEL	Maternal Toxicity, Not Teratogenic
Embryo / Fetal Development	Rat	Oral 5 mg/kg/day	NOAEL	Fetotoxicity, Maternal Toxicity
Embryo / Fetal Development	Rat	Oral 80 mg/kg/day	LOAEL	Maternal Toxicity, Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Fluconazole

<i>In Vitro</i> Bacterial Mutagenicity (Ames)	<i>Salmonella</i> , <i>E. coli</i>	Negative
<i>In Vivo</i> Cytogenetics	Mouse Bone Marrow	Negative
<i>In Vitro</i> Cytogenetics	Human Lymphocytes	Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Fluconazole

24 Month(s)	Rat Female	Oral 10 mg/kg/day	NOAEL	Not carcinogenic
24 Month(s)	Rat Female	Oral 5 mg/kg/day	LOEL	Benign tumors, Liver
24 Month(s)	Mouse	Oral 10 mg/kg/day	NOEL	Not carcinogenic

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview:

The environmental characteristics of this mixture have not been fully evaluated. Based on the concentration of the active ingredient in the formulation, No harmful effects to aquatic organisms are expected.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Fluconazole

<i>Daphnia magna</i> (Water Flea)	LC50	48 Hours	35 mg/L
<i>Pimephales promelas</i> (Fathead Minnow)	LC50	> 50 mg/L	
<i>Cyprinodon variegatus</i> (Sheepshead Minnow)	LC50	> 50 mg/L	

Persistence and Degradability:

No data available

Bio-accumulative Potential:

Partition Coefficient: (Method, pH, Endpoint, Value)

Fluconazole

Predicted Log P 5.0

Mobility in Soil:

No data available

SAFETY DATA SHEET

Material Name: Fluconazole Injection (Hospira, Inc.)
Revision date: 14-Oct-2016

Page 7 of 8
Version: 1.0

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Dextrose, monohydrate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Fluconazole

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 3
EU EINECS/ELINCS List	Schedule 4
	Not Listed

Sodium chloride

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-598-3

Water for Injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present

SAFETY DATA SHEET

Material Name: Fluconazole Injection (Hospira, Inc.)
Revision date: 14-Oct-2016

Page 8 of 8
Version: 1.0

15. REGULATORY INFORMATION

REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Reproductive toxicity, effects on or via lactation; H362 - May cause harm to breast-fed children
Hazardous to the aquatic environment, acute toxicity-Cat.3; H402 - Harmful to aquatic life
Hazardous to the aquatic environment, chronic toxicity-Cat.3; H412 - Harmful to aquatic life with long lasting effects

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information. Safety data sheets for individual ingredients.

Revision date: 14-Oct-2016

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet